Moderna begins late-stage study of RSV vaccine using mRNA technology

A vial and sryinge are viewed in front of a shown Moderna brand in this illustration taken January 11, 2021. REUTERS/Dado Ruvic

Feb 22 (Reuters) – Moderna Inc (MRNA.O) claimed on Tuesday it experienced started a late-phase research of its vaccine for Respiratory Syncytial Virus (RSV) based mostly on the exact same technological know-how utilized to establish its COVID-19 shots.

The only authorized solution employing messenger RNA (mRNA)is COVID-19 vaccine, but Moderna and rival Pfizer (PFE.N) are dashing to tap the opportunity of the technological innovation to focus on conditions these types of as shingles and cancer.

Moderna is acquiring a vaccine for flu making use of mRNA technological innovation and reported on Friday it would create a few additional shots, such as a single for viral infection shingles.

RSV is a frequent respiratory virus that normally leads to chilly-like indications, but which can be major for young kids and older adults.

Moderna produced the decision to start out the late-phase portion of the study immediately after an impartial assessment of preliminary mid-phase information that suggested the vaccine has an satisfactory security profile in older adults.

Reporting by Manas Mishra in Bengaluru Modifying by Arun Koyyur

Our Expectations: The Thomson Reuters Have confidence in Concepts.